Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Abbvie Receives Orphan Drug Designation For Humira® (adalimumab) From The U.s. Food And Drug Administration For The Investigational Treatment Of Moderate-to-severe Hidradenitis Suppurativa (hs) - Yahoo Finance

zithromax for sinus infection holistic treatment for sinus infection

Overprescribing antibiotics worrying for some doctors

The approval of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval for an investigational use. Sponsors must establish safety and efficacy of a compound in the treatment of a disease through adequate and well-controlled studies. About HUMIRA in the U.S. Uses HUMIRA is a prescription medicine used: To reduce the signs and symptoms of: Moderate to severe rheumatoid arthritis (RA) in adults. HUMIRA can be used alone, with methotrexate, or with certain other medicines. HUMIRA may prevent further damage to bones and joints and may help the ability to perform daily activities. Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years of age and older.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/abbvie-receives-orphan-drug-designation-134400655.html

Teva to Present New Respiratory Data at 2015 Annual International Meeting of the American Thoracic Society - Yahoo Finance

When is It Cause for Concern? Short periods of hoarseness following a respiratory infection or after a long or loud period of voice use is not uncommon. With some voice rest, these should resolve within a short period of time. If your hoarseness lasts more than two or three weeks and is not gradually improving, particularly if you smoke or do not have cold-like symptoms, it should prompt a visit to your doctor. If there is significant concern, primary care physicians and emergency department doctors will likely refer patients to an ear, nose and throat doctor (also known as ENT doctor or an otolaryngologist ), who is specially trained to diagnose and treat problems of the larynx. Fortunately, even with prolonged hoarseness, there are rarely truly worrisome or life-threatening conditions, and treatment is usually effective. In the long run, if you have a healthy lifestyle and approach the care of your voice alongside your overall health and wellness, you will keep your voice strong and vigorous.
For the original version including any supplementary images or video, visit http://news.yahoo.com/put-best-voice-forward-110000666.html

Virus could be mistaken for allergy symptoms - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

For example, antibiotics do not fight infections caused by viruses like colds, flu, most sore throats, bronchitis and many sinus and ear infections. The site also notes that antibiotics will not keep others from getting your sickness and they will not help you or your child feel better, but instead can cause side effects like yeast infections and contribute to antibiotic resistance. Some clinics have found a compromise to keep their patients happy. They will write a prescription for antibiotics and tell the patient to hang onto it if their condition worsens.
For the original version including any supplementary images or video, visit http://www.ksat.com/content/pns/ksat/news/2015/05/14/overprescribing-antibiotics-worrying-for-some-doctors.html

Put Your Best Voice Forward - Yahoo News

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our innovative products, especially Copaxone (including competition from orally-administered alternatives, as well as from potential purported generic equivalents) and our ability to migrate users to our 40 mg/mL version; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from the research and development efforts invested in our pipeline of specialty and other products; our ability to reduce operating expenses to the extent and during the timeframe intended by our cost reduction program; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/teva-present-respiratory-data-2015-120000785.html

Download the KFVS News app: iPhone | Android Copyright 2015 KFVS . All rights reserved. Updated: Friday, May 15 2015 11:30 PM EDT2015-05-16 03:30:29 GMT There's sinus infection blood not much difference between the cheap shades and high-end sunglasses when it comes to protection as long as they are labeled. There's not much difference between the cheap shades and high-end sunglasses when it comes to protection as long as they are labeled. Updated: Friday, May 15 2015 11:24 PM EDT2015-05-16 03:24:37 GMT Some people say the Polaris Slingshot looks like the Batmobile. In a sea of everyday, average vehicles, it really sticks out.
For the original version including any supplementary images or video, visit http://www.kfvs12.com/story/29079575/virus-could-be-mistaken-for-allergy-symptoms

Don't be the product, buy the product!